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Background: Adherence to asthma and chronic obstructive pulmonary disease (COPD) treat-
ment has been shown to depend on patient-level factors, such as disease severity, and medication-
level factors, such as complexity. However, little is known about the impact of prescription 
charges – a factor at the health care system level. This study used real-life data to investigate 
whether co-payment affects adherence (implementation and persistence) and disease outcomes 
in patients with asthma or COPD.
Methods: A matched, historical cohort study was carried out using two UK primary care 
databases. The exposure was co-payment for prescriptions, which is required for most patients 
in England but not in Scotland. Two comparison cohorts were formed: one comprising patients 
registered at general practices in England and the other comprising patients registered in Scotland. 
Patients aged 20–59 years with asthma, or 40–59 years with COPD, who were initiated on flutica-
sone propionate/salmeterol xinafoate, were included, matched to patients in the opposite cohort, 
and followed up for 1 year following fluticasone propionate/salmeterol xinafoate initiation. The 
primary outcome was good adherence, defined as medication possession ratio ≥80%, and was 
analyzed using conditional logistic regression. Secondary outcomes included exacerbation rate.
Results: There were 1,640 patients in the payment cohort, ie, England (1,378 patients with 
asthma and 262 patients with COPD) and 619 patients in the no-payment cohort, ie, Scotland 
(512 patients with asthma and 107 patients with COPD). The proportion of patients with good 
adherence was 34.3% and 34.9% in the payment and no-payment cohorts, respectively, across 
both disease groups. In a multivariable model, no difference in odds of good adherence was 
found between the cohorts (odds ratio, 1.04; 95% confidence interval, 0.85–1.27). There was 
also no difference in exacerbation rate.
Conclusion: There was no difference in adherence between matched patients registered in 
England and Scotland, suggesting that prescription charges do not have an impact on adher-
ence to treatment.
Keywords: implementation, adherence, asthma, chronic obstructive pulmonary disease, pre-
scriptions, co-payment
Background
Asthma and chronic obstructive pulmonary disease (COPD) are two leading causes of 
morbidity and economic burden worldwide, with 300 and 210 million people affected, 
respectively.1 Both these diseases are chronic obstructive lung conditions principally 
managed with inhaled therapies, such as inhaled corticosteroids (ICS). Effectiveness of 
therapy, however, can be adversely affected by poor adherence.2 Adherence is defined 
as the process by which patients take their medications as prescribed, comprising 
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1) initiation of treatment, 2) implementation of the dosing 
regimen, and 3) persistence with treatment.3 Previous litera-
ture has demonstrated that poor adherence can exist among 
patients with asthma or COPD4–6 and has an impact on disease 
outcomes.7–9 Contributing factors to poor adherence at the 
patient level include perceived need of treatment,10 fear of 
side effects,11 and ability to use inhaler devices correctly.12,13 
Less research has been done into contributing factors at the 
health care system level.
One potential factor is co-payment for prescriptions. In 
an attempt to scale back on pharmaceutical spending, many 
countries have introduced co-payment policies to offset 
growing drug bills.14–16 A co-payment is a fixed fee for a pre-
scription, which is intended to reduce drug expenditure and 
the collection of medications that have no role in improving 
health.17 However, co-payments may be disadvantageous if 
they result in a decrease in the use of beneficial medication. 
A study in Australia found that a 24% increase in patient 
co-payment for medications had significant effects on the 
dispensing of some essential drugs, including decreased 
volumes of dispensed asthma medications.18 The more vul-
nerable patient populations are those that have an increased 
sensitivity to adverse health outcomes, such as the elderly 
and those with low socioeconomic status.19 A review of 22 
studies in the USA between 1990 and 2003 found that co-
payments were associated with a decrease in the health status 
of older patient groups.20
Currently, in England, for residents nonexempt from 
paying for prescriptions, there is a flat rate patient contribu-
tion of £8.40 per prescription.21 A resident of England can 
cap the prescription cost by purchasing a monthly (£29) or 
annual (£104) prescription prepayment certificate (PPC). In 
contrast, Scotland canceled co-payments on prescriptions in 
2011.22 This difference in prescription payments in England 
and Scotland, and the availability of real-life primary care 
data over time, allows an opportunity to examine the effects 
of prescription co-payment.
The aim of this study was to use real-life data to examine 
the impact of co-payment on maintenance therapy imple-
mentation and persistence and disease outcomes in patients 
with asthma or COPD, accounting for differences between 
the populations.
Methods
Data source and permissions
This study used data from the Optimum Patient Care 
Research Database (OPCRD)23 and the Clinical Practice 
Research Datalink (CPRD).24 Both are primary care databases 
with routinely recorded clinical data from general practices in 
the UK. The OPCRD has anonymized data from >3 million 
patients in >570 UK practices, and the CPRD has anony-
mized data from >5 million patients in >600 UK practices. 
The databases contain a range of information, including 
prescribing activity and diagnoses of disease, identifiable 
by Read codes recorded by clinicians. The CPRD (formerly 
GPRD) is well validated and used frequently for medical and 
health research.24,25 The OPCRD has been used in numerous 
studies of real-life effectiveness in respiratory diseases:26–29 
the validity of the real-life endpoints commonly identified in 
the OPCRD (such as risk-domain asthma control) has been 
supported previously in a study showing the predictive value 
of real-life endpoints for future patient outcomes.30
The OPCRD has ethical approval from the National 
Health Service (NHS) Research Authority to hold and 
process anonymized research data (Research Ethics Com-
mittee reference: 15/EM/0150). This study was approved 
by the Anonymised Data Ethics Protocols and Transparency 
(ADEPT) committee – the independent scientific advisory 
committee for the OPCRD, commissioned by the Respiratory 
Effectiveness Group.31 Informed consent was not required 
from the participants, as this was a retrospective study, and 
all data was anonymized. The study is registered with the 
European Network of Centres for Pharmacoepidemiology 
and Pharmacovigilance (ENCEPP/SDPP/13586).32
Study design
A historical, matched cohort study design was used to com-
pare patients with asthma or COPD with likely co-payment 
with patients with asthma or COPD with no co-payment 
for prescriptions, in terms of their adherence to fluticasone 
propionate/salmeterol xinafoate (FP/SAL) therapy. We chose 
FP/SAL as we aimed to examine adherence to maintenance 
therapy only and so did not select medications that are used 
as both maintenance and reliever therapy. The cohorts will be 
referred to as the payment cohort (patients from general prac-
tices in England) and the no-payment cohort (patients from 
general practices in Scotland). The study period consisted 
of 2 years – a baseline year for patient characterization and 
identification of suitable matching variables and an outcome 
year for observing the outcomes of interest. The baseline and 
outcome years were separated by an index date, which was 
the date of first prescription of FP/SAL.
Inclusion and exclusion criteria
Patients were selected based on the following inclusion 
criteria: diagnosis for asthma and/or COPD; received pre-
scription for FP/SAL, with no prescription in the preceding 
year; aged ≥40 and <60 years at the index date (date of initial 
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 prescription of FP/SAL) for patients with COPD, and aged 
≥20 and <60 years at the index date for patients with asthma; 
at least 2 years of valid, continuous data (at least 1 year before 
and at least 1 year after the index date); and at least one fur-
ther prescription for FP/SAL during the outcome period. The 
upper age boundary of 60 years was used because patients 
aged ≥60 years are exempt for co-payment in England.
Patients were excluded if they had any chronic respira-
tory disease other than asthma or COPD, at any time, or 
they met other conditions for co-payment exemption, which 
included being pregnant during or in the 12 months prior to 
the study period, record of “prescription exemption status” 
before or during the study period, and hospitalization during 
the study period.
Patients with only an asthma diagnosis were considered 
the “asthma group”, and patients with a COPD diagnosis, 
who may or may not have had an asthma diagnosis in addi-
tion, were considered the “COPD group”. Thus, there was 
no overlap between the two groups.
Outcome measures
The primary outcome was adherence to FP/SAL therapy over 
the 1-year outcome period. This was evaluated in terms of the 
percentage of prescription refill rate, with good adherence 
being defined as a medication possession ratio (MPR)33 of 
≥80%. The normal duration of a prescription in the UK is 
30 days. Since the MPR was assessed in a fixed 1-year period, 
this adherence measure incorporates both implementation 
and persistence. Details of the calculations used to compute 
MPR can be found in the Supplementary materials.
Secondary outcome measures included number of severe 
exacerbations (or moderate/severe exacerbations for patients 
in the COPD group), risk-domain control, average daily dose 
of short-acting beta
2
 agonist (SABA), and number of acute 
respiratory events (patients in asthma group).
The definition of severe asthma exacerbations was the 
sensitive definition based on the American Thoracic Society/
European Respiratory Society (ATS/ERS) guidelines.34 A 
severe exacerbation included one or more occurrences of 
any of the following: asthma-related hospital admission or 
accident and emergency (A&E) attendance and an acute 
course of oral corticosteroids (OCS) with lower respiratory 
consultation.
For patients in the COPD group, a moderate or severe 
exacerbation included one or more occurrences of any of 
the following: COPD-related, unscheduled hospital admis-
sion or A&E attendance; an acute course of OCS with lower 
respiratory consultation; and antibiotics prescribed with 
lower respiratory consultation. The risk-domain control of 
COPD was defined as the absence of any moderate/severe 
exacerbations.
For patients in the asthma group, an acute respiratory 
event was defined as one or more occurrences of any of the 
following: asthma-related hospital admission or A&E atten-
dance; an acute course of OCS; and antibiotics prescribed 
with lower respiratory consultation. The risk-domain control 
of asthma was defined as the absence of any acute respira-
tory events.
Finally, the average daily dose of SABA during the out-
come year was calculated as the average number of puffs per 
day over the year multiplied by the strength of dose (in mg of 
salbutamol equivalents).
More detailed definitions of the above outcomes can be 
found in the Supplementary materials.
Statistical analysis
Baseline characterization
Baseline variables were summarized and compared between 
cohorts. This was done separately in the asthma and COPD 
groups to identify potential matching variables, ie, those 
that differed between cohorts. Binary and categorical 
variables were summarized using counts and percentages 
by category. Continuous variables were summarized using 
mean and standard deviation or median and interquartile 
range. Variables were compared between cohorts to assess 
imbalance and bias potential. Imbalance was measured using 
the standardized mean difference (SDD)35 between cohorts, 
while bias potential was measured using the relative change 
in coefficient (RCC).36
Matching
The baseline variables with high bias potential (>2%) and 
high level of imbalance (SDD >10%)37 were considered 
for matching. This was done separately within the asthma 
group and the COPD group, ie, patients with asthma only 
were matched with patients with asthma only (which formed 
the matched asthma group) and patients with COPD were 
matched with patients with COPD (which formed the 
matched COPD group), regardless of coexisting asthma 
diagnosis. Exact matching combined with a propensity score 
was carried out with a mixture of ratios of patients in the no-
payment cohort to patients in the payment cohort (1:1, 1:2, 
and 1:3). After matching, bias potential was again assessed 
to identify areas where residual confounding was present for 
the different outcomes. More details on matching methods 
can be found in the Supplementary materials.
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Outcome analysis
Conditional logistic regression was used to compare the odds 
of good adherence of patients in the payment cohort with 
that of the matched patients in the no-payment cohort. This 
was carried out in the asthma and COPD groups combined.
Conditional logistic regression was used to estimate odds 
ratios (ORs) for risk-domain control, comparing the payment 
cohort with the no-payment cohort. Conditional Poisson 
regression was used to estimate rate ratios (RRs), for the 
number of severe exacerbations (or moderate/severe in the 
COPD group) and the number of acute respiratory events (in 
the asthma group only). Finally, ordinal logistic regression 
was used to estimate the proportional odds of being in a 
higher category of SABA dose. For this analysis, the average 
daily dose of SABA was categorized as 0, >0–200, >200–400, 
>400–600, and >600 µg/day (salbutamol equivalent). These 
categories have been used in previous studies.38,39
In all cases, multivariable models were fitted, adjusting 
for identified residual confounders, and model estimates 
were computed with 95% confidence intervals (CIs). The 
level of statistical significance was set at 5%. The study 
had 90% power to detect a difference in the proportion of 
adherent patients of 7.7%, with a two-sided significance of 
5%. All statistical analyses were carried out using Stata MP6 
Version 12 and Stata SE Version 14 (StataCorp, College 
Station, TX, USA).
Sensitivity analysis
The analysis of the primary outcome was repeated in a sub-
group of patients who had evidence of 9 months (270 days) 
of persistent use of FP/SAL medication. This meant that the 
patient received prescription for FP/SAL continuously over 
9 months, with no more than 30 days between the dates of 
issue of prescriptions. Discontinuation was defined as having 
no repeat prescription of FP/SAL in 6 months (180 days).
The main analysis was carried out in cohorts deriving 
from all three matching ratio strategies, ie, 1:1, 1:2, and 
1:3. A sensitivity analysis was carried out using cohorts that 
resulted from the 1:3 matching strategy only.
Results
Patients
After applying study criteria, 6,716 patients with asthma 
or COPD were available from the primary care databases. 
Details of specific inclusions and exclusions are shown in 
Figure S1. Of the 6,716 unmatched patients, 6,000 were 
likely to require co-payments (ie, registered in England) and 
716 were not required to pay for prescriptions (ie, registered 
in Scotland). After matching, these figures were reduced 
to 1,640 patients in the payment cohort and 619 patients 
in the no-payment cohort. Of the payment cohort, 1,378 
patients had asthma only and 262 patients had COPD, and 
of the no-payment cohort, 512 patients had asthma only and 
107 patients had COPD (Table 1).
An overview of the variables with relevant differences 
between the cohorts is listed in Table S1. The proportions of 
patients matched 1:1, 1:2, or 1:3 are listed in Table S2 and 
show that the majority of patients were matched to three 
others.
Baseline characteristics of the matched cohorts, with 
disease groups combined, are listed in Tables 2 and 3. Patients 
had a mean age of 44 years in both cohorts; 47–48% of them 
were male, 28–30% of them were current smokers, and 
35–36% of them had a body mass index (BMI) of ≥30. All 
of these characteristics were well matched between cohorts, 
such that P-values for comparison were nonsignificant, and 
SDDs were <10%. Prevalence of comorbidities was similar 
between cohorts, and the median Charlson comorbidity index 
(CCI) was 4.0 (Table 2).
The average daily dose of SABA was >600 µg/day in 
11.2% of the patients in the payment cohort and 13.1% 
of the patients in the no-payment cohort, and ~15% of the 
patients in each cohort had two or more prescriptions of 
OCS, during the baseline year (Table 3). Approximately 
42–45% of the patients with asthma had at least one severe 
exacerbation and 30–32% of the patients with COPD had 
at least one moderate or severe exacerbation. All baseline 
variables had an SDD of <10%, indicating good balance 
between the matched cohorts. Definitions of the baseline 
variables in Table 3 are found in the Supplementary materi-
als. Further baseline characteristics are listed in Table S3. 
Baseline characteristics for the asthma and COPD groups 
separately are listed in Tables S4–S6.
Primary outcome
During the outcome year, 34.3% of the patients in the pay-
ment cohort and 34.9% of the patients in the no-payment 
cohort had good adherence to FP/SAL therapy (ie, MPR 
Table 1 Number of patients by cohort and disease group
Disease 
group
Unmatched (n=6,716) Matched (n=2,259)
Payment 
cohort
No-payment 
cohort
Payment 
cohort
No-payment 
cohort
Asthma 4,882 582 1,378 512
COPD 1,118 134 262 107
Total 6,000 716 1,640 619
Abbreviation: COPD, chronic obstructive pulmonary disease.
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≥80%). This proportion was lower in patients with asthma 
(31.4% in both cohorts) and higher in patients with COPD 
(49.6 and 51.4% in the payment and no-payment cohorts, 
respectively; Table 4). In unadjusted comparisons, adherence 
was not significantly different between cohorts (P=0.801). 
The distribution of the adherence levels is shown graphically 
in Figure 1. Summary outcome data for the asthma and COPD 
groups separately are listed in Table S7.
When adjusting for potential confounders, the adjusted 
OR for adherence across both disease groups was 1.04 (95% 
CI, 0.85–1.27; Table 5), comparing the payment cohort with 
the no-payment cohort, showing that adherence was similar 
between cohorts. Variables used for adjusting were selected 
based on the residual confounding observed (Table S8).
Secondary outcomes
During the outcome year, 62–64% of the patients with asthma 
achieved risk-domain control and 45–47% of the patients with 
COPD achieved risk-domain disease control (Table 4). These 
proportions were not significantly different between cohorts. 
There were fewer exacerbations in the outcome year, but exac-
erbations remained similar between cohorts. Furthermore, 
there was no difference between acute respiratory events (in 
patients with asthma) and the average daily dose of SABA, 
when cohorts were compared in unadjusted analyses (Table 4).
When adjusting for residual confounders, the adjusted 
ORs for risk-domain control were 0.89 (95% CI 0.71–1.11) in 
patients with asthma and 0.89 (95% CI 0.53–1.48) in patients 
with COPD (Table 5). Adjusted RRs for severe exacerbations 
(or moderate/severe exacerbations in COPD) were 1.01 (95% 
CI 0.85–1.21) in patients with asthma and 1.27 (95% CI 
0.98–1.65) in patients with COPD, comparing the payment 
cohort with the no-payment cohort. None of these associations 
were statistically significant. For patients with asthma, there 
was no difference between cohorts in terms of acute respira-
tory events (RR 1.10; 95% CI 0.96–1.27), after adjustment 
Table 2 Baseline demographic characteristics and comorbidities in combined disease groups, by matched cohort
Variables Payment cohort  
(n=1,640)
No-payment cohort  
(n=619)
P-valuea SDD
Index year, n (%) 0.176 5.9
2012 879 (53.6) 322 (52.0)
2013 509 (31.0) 191 (30.9)
2014 231 (14.1) 90 (14.5)
2015 21 (1.3) 16 (2.6)
Age, mean (SD) 44.0 (11.1) 44.4 (11.2) 0.341 3.7
Male, n (%) 775 (47.3) 298 (48.1) 0.707 1.8
Smoking status, n (%) 0.687 3.6
Never smoked 762 (46.5) 275 (44.4)
Current smoker 469 (28.6) 184 (29.7)
Exsmoker 409 (24.9) 160 (25.8)
BMI (kg/m2), n (%) 0.356 2.5
<18.5 15 (0.9) 11 (1.8)
18.5–<25 557 (34.0) 206 (33.3)
25–<30 478 (29.1) 186 (30.0)
≥30 590 (36.0) 216 (34.9)
Comorbidities, n (%)
Cardiovascular disease 114 (7.0) 41 (6.6) 0.784 1.3
Ischemic heart disease 37 (2.3) 13 (2.1) 0.822 1.1
Hypertension 218 (13.3) 80 (12.9) 0.817 1.1
Cancer 142 (8.7) 70 (11.3) 0.054 8.8
Diabetes 76 (4.6) 36 (5.8) 0.249 5.3
Rhinitis 469 (28.6) 191 (30.9) 0.292 4.9
Active rhinitis 191 (11.6) 81 (13.1) 0.349 4.4
Gastroesophageal reflux disease 166 (10.1) 73 (11.8) 0.249 5.3
Active gastroesophageal reflux disease 121 (7.4) 49 (7.9) 0.666 2.0
Eczema 486 (29.6) 170 (27.5) 0.311 4.8
Active eczema 31 (1.9) 14 (2.3) 0.573 2.6
Pneumonia 72 (4.4) 24 (3.9) 0.590 2.6
Oral candidiasis 15 (0.9) 7 (1.1) 0.641 2.1
Charlson comorbidity index, median (IQR) 4.0 (4.0) 4.0 (4.0) 0.554 3.1
Note: aP-value estimated from Kruskal–Wallis equality-of-populations rank test, or the Pearson’s chi-square test of independent categories, where appropriate.
Abbreviations: SDD, standardized mean difference; SD, standard deviation; BMI, body mass index; IQR, interquartile range.
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for confounders.  Proportional ORs for the average daily dose 
of SABA showed no difference in odds of being in a higher 
category of SABA dose in the payment cohort than in the 
no-payment cohort. Definitions of variables used to adjust the 
outcome models can be found in the Supplementary materials.
Sensitivity analyses
Since the adherence measure (MPR in a fixed 1-year period) 
included both implementation and persistence, a sensitivity 
analysis was performed, restricting the population to patients 
with at least 9 months of persistent use of FP/SAL after 
initiation. Of the matched cohorts, 80.2% of the patients 
in the payment cohort and 77.7% of the patients in the no-
payment cohort met this criterion. In this subgroup, 42.1% of 
the patients in the payment cohort and 44.3% of the patients 
in the no-payment cohort had good adherence to treatment, 
in both disease groups combined (Table 4). In an adjusted 
model, there was no significant difference between cohorts 
in terms of adherence (Table S9).
Results were similar in sensitivity analysis restricted to 
patients matched 1:3 (Table 5). One exception, however, 
was in the comparison of severe exacerbations in the asthma 
group, which found that patients in the payment cohort had 
double the rate of exacerbations as patients in the no-payment 
cohort (RR, 2.03; 95% CI, 1.05–3.93).
The main analysis investigated adherence in both disease 
groups combined, but an ad hoc sensitivity analysis was car-
ried out in patients with asthma only. This was due to poorer 
matching of patients with COPD, evidenced by the presence 
of residual confounding. Patients with COPD were, therefore, 
excluded to test the robustness of the main results. In patients 
with asthma only, there was no difference in adherence 
between the two cohorts and no difference in the subgroup 
with 9 months of persistence (Table S9).
Discussion
This study showed that patients with asthma or COPD regis-
tered at general practices in England – who were likely to pay 
for their prescriptions – and patients with asthma or COPD 
registered in Scotland – who were not paying for prescrip-
tions – had similar adherence to FP/SAL therapy. This was 
observed after matching by demographic characteristics and 
Table 3 Baseline clinical characteristics in combined disease groups, by matched cohort
Variables Payment cohort 
(n=1,640)
No-payment cohort 
(n=619)
P-valuea SDD
Average daily dose of SABA (µg, salbutamol equivalent), n (%) 0.597 6.9
0 745 (45.4) 270 (43.6)
>0–≤200 397 (24.2) 144 (23.3)
>200–≤400 221 (13.5) 82 (13.2)
>400–≤600 94 (5.7) 42 (6.8)
>600 183 (11.2) 81 (13.1)
Any OCS prescriptions, n (%) 0.864 2.2
0 1,132 (69.0) 420 (67.9)
1 259 (15.8) 102 (16.5)
≥2 249 (15.2) 97 (15.7)
Antibiotic prescriptions, with LR consultation,b n (%) 0.432 5.5
0 1,108 (67.6) 406 (65.6)
1 317 (19.3) 119 (19.2)
≥2 215 (13.1) 94 (15.2)
A&E attendances (at least 1), n (%) 4 (0.2) 2 (0.3) 0.744 1.5
Outpatient visitsc (at least 1), n (%) 33 (2.0) 13 (2.1) 0.895 0.6
Moderate/severe exacerbations (COPD), n (%) 0.688 5.6
0 941 (57.4) 339 (54.8)
1 376 (22.9) 147 (23.7)
2 199 (12.1) 80 (12.9)
≥3 124 (7.6) 53 (8.6)
Severe exacerbations (asthma), n (%) 0.845 4.0
0 1,141 (69.6) 422 (68.2)
1 306 (18.7) 117 (18.9)
2 121 (7.4) 48 (7.8)
≥3 72 (4.4) 32 (5.2)  
Notes: aP-value estimated from Kruskal–Wallis equality-of-populations rank test, or the Pearson’s chi-square test of independent categories, where appropriate. bLR 
consultations were identified by: Read codes (including asthma, COPD and LRTI); asthma/COPD review codes excluding any monitoring letter codes; and lung function and/
or asthma monitoring. cOutpatient visits for asthma or LR code or generic outpatient code on same day as respiratory consultation.
Abbreviations: SDD, standardized mean difference; SABA, short-acting beta2 agonist; OCS, oral corticosteroids; LR, lower respiratory; LRTI, lower respiratory tract 
infection; A&E, accident and emergency; COPD, chronic obstructive pulmonary disease.
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other studies.9,40–43 In terms of the association between co-
payments for prescription and adherence, the current study 
was not consistent with recent literature. A meta-analysis 
published in 2013,44 which included only US studies of 
varying medication types, estimated an overall increase 
in odds of nonadherence of 11% in co-payment versus no 
co-payment. The authors noted several limitations of the 
results, however – that the follow-up times varied between 
studies, between 3 months and 2 years, and that the quality 
of studies was poor in some cases. Another meta-analysis on 
studies done in the USA or Canada45 found that 56 of the 66 
studies reported an inverse relationship between co-payment 
and adherence, with 10 studies reporting a nonsignificant 
relationship, or limited data to detect a relationship. These 
studies also covered a range of medication types. The 
authors acknowledged that the analysis of adherence should 
account for factors affecting adherence, such as disease 
severity, and that this was not done consistently across the 
studies included. The review covered two studies on ICS. 
One study, using electronic medical records, did not find a 
difference in adherence between co-payment levels.46 The 
second study, using pharmacy records, showed a significant 
negative association with cumulative co-payment level and 
implementation adherence.40 Another study in the same 
patient population in Pennsylvania showed that patients with 
higher co-payment costs were less likely to initiate asthma 
medication.47 A discrete choice experiment of patients with 
COPD from the USA showed medication costs for the 
patients to be an important factor in treatment decisions.48
An explanation for the inconsistency between the cur-
rent study and what is reported in the literature could be 
publication bias: negative studies tend to be less likely to be 
published,49 but this only counts for studies with the asso-
ciation between co-payment and adherence as their main 
Table 4 Summary of outcomes, by cohort
Variables, n (%) Payment 
cohort 
(n=1,640)
No-payment 
cohort (n=619)
P-valuea
Adherence achieved (MPR >80%)
Both disease groups 563 (34.3) 216 (34.9) 0.801
Asthma group 433 (31.4) 161 (31.4) 0.992
COPD group 130 (49.6) 55 (51.4) 0.756
With 9-month 
persistenceb
554 (42.1) 213 (44.3) 0.414
Risk domain control achieved
Asthma group 854 (62.0) 325 (63.5) 0.549
COPD group 117 (44.7) 50 (46.7) 0.717
Severe asthma exacerbations 0.950
0 1,053 (76.4) 389 (76.0)
1 216 (15.7) 79 (15.4)
2 70 (5.1) 27 (5.3)
≥3 39 (2.8) 17 (3.3)
Moderate/severe COPD 
exacerbations
0.393
0 117 (44.7) 50 (46.7)
1 62 (23.7) 26 (24.3)
2 31 (11.8) 17 (15.9)
≥3 52 (19.8) 14 (13.1)
Acute respiratory events, 
asthma
0.865
0 854 (62.0) 325 (63.5)
1 341 (24.7) 121 (23.6)
2 103 (7.5) 40 (7.8)
≥3 80 (5.8) 26 (5.1)
SABA, average daily 
dose (µg/day, salbutamol 
equivalent), asthma
0.706
0 463 (33.6) 174 (34.0)
>0–≤200 389 (28.2) 133 (26.0)
>200–≤400 257 (18.7) 98 (19.1)
>400–≤600 121 (8.8) 42 (8.2)
>600 148 (10.7) 65 (12.7)
SABA, average daily 
dose (µg/day, salbutamol 
equivalent), COPD
0.155
0 74 (28.2) 33 (30.8)
>0–≤200 52 (19.8) 14 (13.1)
>200–≤400 48 (18.3) 28 (26.2)
>400–≤600 46 (17.6) 12 (11.2)
>600 42 (16.0) 20 (18.7)
Notes: aP-value estimated from Kruskal–Wallis equality-of-populations rank test, 
or the Pearson’s chi-square test of independent categories, where appropriate. bA 
total of 80.2% of the patients in the payment cohort and 77.7% of the patients in the 
no-payment cohort had 9 months of persistent use of FP/SAL.
Abbreviations: MPR, medication possession ratio; COPD, chronic obstructive 
pulmonary disease; SABA, short-acting beta2 agonist; FP/SAL, fluticasone propionate/
salmeterol xinafoate.
Figure 1 Distribution of medication possession ratio (%) in matched cohorts.
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indicators of disease severity and after adjusting for residual 
confounding.
The level of adherence to maintenance therapy observed 
in this study – ~35% in patients with asthma and 50% in 
patients with COPD – was within the range reported in 
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objective. The cited studies came from the USA and Canada. 
Cultural and socioeconomic differences existing between 
these countries and the UK could be another explanation for 
the discrepancy in findings.
This study found no difference in disease outcomes 
between patients likely paying for prescriptions and patients 
not paying for prescriptions in the majority of cases. The 
association between adherence and effectiveness of treat-
ment has been demonstrated previously,9 and hence it is 
unsurprising that matched cohorts with similar adherence 
would observe similar disease outcomes. However, there was 
some inconsistency in the results: patients in the payment 
cohort were found to have significantly more severe asthma 
exacerbations than those in the no-payment cohort when the 
analysis was restricted to cohorts derived from one matching 
strategy, rather than a mixture of matching strategies. This 
inconsistency cannot easily be explained but is potentially an 
anomaly as the results were consistent on all other endpoints.
The strength of this study is its size and the real-life 
data used, which is likely to be representative of patients 
with asthma and patients with COPD. Furthermore, the 
length of follow-up allowed for a good measure of adher-
ence to be estimated. As this was an observational study 
to compare two cohorts, methods were applied to ensure 
that the cohorts were as similar as possible, so that asso-
ciations with the exposure (co-payment of prescriptions, 
or no co-payment of prescriptions) could be studied. The 
study design included matching patients based on important 
demographic and clinical factors and adjusting models by 
further potential confounders. When the level of residual 
confounding was high, as was observed in the COPD group, 
ad hoc analyses were carried out in the asthma group only, 
but the exclusion of the COPD group did not appear to 
impact the results.
Limitations
Limitations of the current study include the possibility of 
residual confounding. Despite matching methods and adjust-
ment for measured confounders, the nature of the study – 
being observational, rather than a randomized controlled 
trial – is such that confounding by unmeasured variables 
may be present in the results. Medication-taking behavior 
can be affected by many factors. Such factors may be sub-
jective and unique to the patients – for example, attitude 
toward the health care system and personal perception of 
their disease. This is an added difficulty in the analysis of 
adherence.50 Furthermore, the two cohorts being compared 
in this study were from different geographical locations 
in the UK, which are known to differ in terms of chronic 
disease and life expectancy.51,52 Matching by the history of 
disease outcomes will have gone some way to alleviate dif-
ferences between patients in England and Scotland, and the 
study cohorts were well-matched in terms of comorbidities. 
Other potential differences, such as income of the patients, 
Table 5 Results of adjusted outcome models
Outcome variable All matching ratios used (N=2,259) Only 1:3 matching ratio used 
(N=1,928)
Adjusted odds ratio/rate  
ratioa (with 95% CI)
P-value Adjusted odds ratio/rate 
ratioa (with 95% CI)
P-value
Combined disease groups
Adherenceb 1.04 (0.85–1.27) 0.704 1.58 (0.80–3.14) 0.191
Asthma
Risk-domain controlb 0.89 (0.71–1.11) 0.294 0.56 (0.27–1.17) 0.125
Number of severe exacerbationsc 1.01 (0.85–1.21) 0.907 2.03 (1.05–3.93) 0.035
Number of acute respiratory eventsd 1.10 (0.96–1.27) 0.163 1.56 (0.99–2.47) 0.055
SABA average daily dosee 1.05 (0.86–1.27) 0.655 1.22 (0.61–2.47) 0.576
COPD
Risk-domain controlf 0.89 (0.53–1.48) 0.641 NC
Number of moderate/severe exacerbationsg 1.27 (0.98–1.65) 0.067 NC
SABA average daily doseh 1.03 (0.65–1.63) 0.907 NC  
Notes: NC means model did not reach convergence. aOdds/rate ratios compare payment cohort with no-payment cohort. bAdjusted by antibiotic prescriptions with 
lower respiratory indication. cAdjusted by acute OCS courses (sensitive definition) LTRA prescription, and maintenance OCS prescription. dAdjusted by antibiotic 
prescriptions with lower respiratory indication and LTRA prescription. eAdjusted by the average daily dose of SABA. fAdjusted by eczema, cancer, active gastroesophageal 
reflux disease, rhinitis, number of SABA inhalers, any OCS prescription and acute OCS course (sensitive definition). gAdjusted by ICS prescriptions, acute OCS 
prescriptions (probable definition), SABA inhaler prescriptions, Medical Research Council dyspnea score, and GOLD severity. hAdjusted by average daily dose of SABA 
and GOLD severity.
Abbreviations: CI, confidence interval; SABA, short-acting beta2 agonist; COPD, chronic obstructive pulmonary disease; NC, no convergence; OCS, oral corticosteroids; 
LTRA, leukotriene receptor antagonist; ICS, inhaled corticosteroids; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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could not be accounted for in these data. The results did not 
include practice-level clustering and, therefore, may have 
been affected by potential differences between practices, 
such as the level of health education offered. In addition, 
despite the quality of the databases used, it cannot be guar-
anteed that all information is complete.53
The study did not distinguish between the three compo-
nents of adherence (initiation, implementation, and persis-
tence). By requiring at least two prescriptions for a patient 
to be included in the study, we excluded patients who did not 
initiate their prescribed treatment. Therefore, our study was 
not able to detect differences in that aspect of adherence. In 
a sensitivity analysis restricting the population to patients 
with at least 9 months of persistent FP/SAL use, we showed 
that our conclusion of no difference in adherence between 
the payment and no-payment cohorts was not driven by the 
inclusion of nonpersistent patients.
We did not exclude patients who switched to other ICS 
medication, and such patients will have appeared to have 
poor adherence to FP/SAL therapy in our dataset. However, 
since the observed adherence levels were within the range of 
results from other studies, and both cohorts are likely to have 
been affected equally, we do not think this affected the results.
Our algorithm for MPR did not adjust observed prescrip-
tion dates and durations for stockpiling, dose changes, or 
medication switches, which could have resulted in a reduced 
precision of adherence quantification.
The study endeavored to exclude patients registered in 
general practices in England who were exempt from prescrip-
tion charges. This was done by searching for common reasons 
for exemption, such as pregnancy, and by searching for a 
record of exemption status. In doing this, the study relied on 
the accuracy of the primary care source databases. It is likely 
that the vast majority of patients with exemptions have been 
excluded, but it remains a possibility that a small proportion 
of exempt patients were in the study sample.
Conclusion
Patient adherence is vital if treatment is to be effective. At 
a time when prescription costs are high and put a strain on 
the health care system,54 it is important to ascertain whether 
measures to relieve the strain – such as co-payments – have an 
adverse effect on adherence to treatment, and consequently, 
on patient outcomes. In this study, there was no difference in 
adherence between matched patients registered in England 
and Scotland, suggesting that prescription charges do not 
have an impact on adherence to maintenance therapy for 
asthma or COPD.
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